By Sabela Ojea
Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat metastatic pancreatic ductal cancer.
The stock was up 12% to $9.73 in pre-market trading.
The clinical-stage biopharmaceutical company said that the trial has shown that the combination of the treatments statistically increases in one-year the survival rate and median overall survival when compared to taking gemcitabine/nab-paclitaxel alone.
Pancreatic ductal adenocarcinoma is the common type of this lethal disease, with an average five-year survival rate of less than 10%, according to the National Institutes of Health.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 17, 2024 08:52 ET (13:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.